Abstract
TIM-3 (T cell immunoglobulin and mucin-domain containing protein 3) is a member of the TIM family of proteins that is preferentially expressed on Th1 polarized CD4+ and CD8+ T cells. Recent studies indicate that TIM-3 serves as a negative regulator of T cell function (i.e. T cell dependent immune responses, proliferation, tolerance, and exhaustion). Despite having no recognizable inhibitory signaling motifs, the intracellular tail of TIM-3 is apparently indispensable for function. Specifically, the conserved residues Y265/Y272 and surrounding amino acids appear to be critical for function. Mechanistically, several studies suggest that TIM-3 can associate with interleukin inducible T cell kinase (ITK), the Src kinases Fyn and Lck, and the p85 phosphatidylinositol 3-kinase (PI3K) adaptor protein to positively or negatively regulate IL-2 production via NF-κB/NFAT signaling pathways. To begin to address this discrepancy, we examined the effect of TIM-3 in two model systems. First, we generated several Jurkat T cell lines stably expressing human TIM-3 or murine CD28-ECD/human TIM-3 intracellular tail chimeras and examined the effects that TIM-3 exerts on T cell Receptor (TCR)-mediated activation, cytokine secretion, promoter activity, and protein kinase association. In this model, our results demonstrate that TIM-3 inhibits several TCR-mediated phenotypes: i) NF-kB/NFAT activation, ii) CD69 expression, and iii) suppression of IL-2 secretion. To confirm our Jurkat cell observations we developed a primary human CD8+ cell system that expresses endogenous levels of TIM-3. Upon TCR ligation, we observed the loss of NFAT reporter activity and IL-2 secretion, and identified the association of Src kinase Lck, and PLC-γ with TIM-3. Taken together, our results support the conclusion that TIM-3 is a negative regulator of TCR-function by attenuating activation signals mediated by CD3/CD28 co-stimulation.
Highlights
Immune check-point receptors expressed on T cells have emerged as important targets for the development of cancer immunotherapies
Given the importance of the NFAT and NF-κB transcription factors in T cell receptor (TCR)-induced signaling and the combined observations that TIM-3 expressing cells have decreased IL-2 expression and NFAT activity in phorbol myristate acetate (PMA) stimulated primary and Jurkat T cells [35], we evaluated whether TIM-3 suppresses transcriptional reporter activity in TIM-3+, primary human CD8+ T cells
The results presented demonstrate that TIM-3 serves a negative regulatory role in mitigating activation signals derived from the T cell receptor complex
Summary
Immune check-point receptors expressed on T cells have emerged as important targets for the development of cancer immunotherapies (rev. in [1, 2]). Immune check-point receptors expressed on T cells have emerged as important targets for the development of cancer immunotherapies During chronic infections and cancer, a sustained state of T cell dysfunction emerges in which the normal effector functions of individual T cell subsets are lost. In the context of cancer, the deregulated expression of checkpoint receptors serves as an important mechanism of cancer cell immune resistance. Much attention has focused on targeting the CTLA-4 and PD-1 pathway, including the receptor and its cognate ligands PD-L1/L2, as potential immunotherapy due mostly in part to its broad expression on immune cells, their function within the tumor microenvironment [4, 5] and its well characterized role in the TCR signaling pathway [6,7,8,9,10,11]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.